Étiquette : USA

Marijuana and acute health care contacts in Colorado, George SamWang et al., 2017

Marijuana and acute health care contacts in Colorado George SamWang, Katelyn Hall, Daniel Vigil, Shireen Banerji, AndrewMonte, Mike VanDyke Preventive Medicine, 2017, 104, 24-30. doi: 10.1016/j.ypmed.2017.03.022   a b s t r a c t Over 22 million Americans are current users of marijuana; half of US states allow medical marijuana, and several allow recreational marijuana. The objective of this study was to evaluate the impact marijuana has on hospitalizations, emergency department (ED) visits, and regional poison center (RPC) calls in Colorado, a medical and recreational marijuana state. This is a retrospective review using Colorado Hospital Association hospitalizations and ED visits with marijuana-related billing codes, and [...]

Lire la suite

California Psilocybin Decriminalization Initiative, Amanda Feilding, Beckley Foundation, 2019

California Psilocybin Decriminalization Initiative   The Beckley Foundation is proud to announce its partnership with Decriminalize California (the California Psilocybin Decriminalization Initiative 2020), an open-source citizens’ initiative which would: legalize psilocybin mushrooms and their extracts and derivatives for therapeutic and medical use, and decriminalize it for personal, spiritual and religious use; allowing people to cultivate and use psilocybin mushrooms in their own home and on privately-owned property; and enabling those convicted of psilocybin-related crimes to have their sentences reviewed and, when appropriate, have their criminal records expunged. You can read the full press release here. The initiative decriminalizes psilocybin use by adults aged 18+. [...]

Lire la suite

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013, Deborah S. Hasin et al., 2017

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013 Deborah S. Hasin, Aaron L. Sarvet, Magdalena Cerda, Katherine M. Keyes, Malka Stohl, Sandro Galea, Melanie M. Wall JAMA Psychiatry, 2017, 74, (6), 579–610. Doi: 10.1001/jamapsychiatry.2017.0724 PMCID: PMC5539836      PMID: 28445557 Key Points Question Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s? Findings In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118 497 participants, the risk for cannabis use and cannabis use disorders increased at a significantly greater [...]

Lire la suite

Une université de Houston teste la psilocybine pour la dépression résistante aux traitements, Aurelien BERNARD, Newsweed, 22 octobre 2019.

Une université de Houston teste la psilocybine pour la dépression résistante aux traitements -                 www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD   Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]

Lire la suite

A Psychotherapeutic View on the Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Addiction, Anja LOIZAGA-VELDER, 2013

A Psychotherapeutic View on the Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Addiction Anja LOIZAGA-VELDER MAPS Bulletin Special Edition, Spring 2013, 36-40.   Ayahuasca is a traditional plant preparation of the Amazon basin with psychoactive properties. In recent decades ayahuasca has gained the attention of researchers in multiple disciplines worldwide due to its acclaimed therapeutic and spiritual qualities. It is an admixture of two plants : the harmaline containing vine Banisteriopsis caapi, and the DMT-containing leafs from the Psychotria viridis bush. It is typically administered by a trained expert in a ritual context. The use of ayahuasca has spread beyond the Amazon [...]

Lire la suite

Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults, Gerard Ngueta & Ruth Ndjaboue, 2019

Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults Gerard Ngueta, Ruth Ndjaboue Journal of Diabetes, 2019 https://doi.org/10.1111/1753-0407.12958 Abstract Background Obese individuals are more likely to show insulin resistance (IR). However, limited population studies on marijuana use with markers of IR have yielded mixed results. The aim of this study was to examine the association of marijuana use with IR in US adults with different body mass index (BMI) status. Methods Data from the 2009 to 2016 National Health and Nutrition Examination Survey (NHANES) were abstracted. Minimal lifetime marijuana use was estimated using the duration of regular exposure and frequency of use. [...]

Lire la suite

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum, Theodore GREINER et al., 1958

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert  EDELBERG AMA, Archives of  Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]

Lire la suite

LSD Psychotherapy by Stanislas GROF, 1997

LSD Psychotherapy Stanislas GROF Hunter House Ed., 1979   LIST OF CONTENTS 1. History of LSD Therapy The Discovery of LSD and its Psychedelic Effects Early Laboratory and Clinical LSD Research Therapeutic Experimentation With LSD Studies of Chemotherapeutic Properties of LSD LSD-Assisted Psychotherapy The Need for a Comprehensive Theory of LSD Therapy 2. Critical Variables in LSD Therapy Pharmacological Effects of LSD Personality of the Subject Personality of the Therapist or Guide Set and Setting of the Sessions 3. Psycholytic and Psychedelic Therapies with LSD : Towards an Integration of Approaches The Search for an Effective Technique of LSD Psychotherapy Advantages and Drawbacks of the Psycholytic Approach Pros and Cons of Psychedelic Therapy 4. Principles of LSD Psychotherapy The Preparation Period Psychedelic Sessions Integration [...]

Lire la suite

Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography, Torsten Passie, 1997

Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography Torsten Passie Laurentius Publishers, Hannover, Germany, 1997 Kleine bibliographische Reihe, vol. 3. (Ed. Raimund Dehmlow), ISSN 0941-6617 ISBN 3-931614-83-2 (cloth), ISBN 3-931614-84-0 (pbk)   Preface I. Introduction     9 II. Organization of the Bibliography     21 III. Bibliography 1. General Approach and Basic Research    23 2. Psycholytic Therapy     42 3. Psychedelic Therapy    70 IV. Major Scientific Conferences on the Subject    88 V. Major Bibliographic Sources   89 Author Index    90 Subject Index    95 About the Authors     102  

Lire la suite

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration, Matthew Oram, 2016

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]

Lire la suite